|
Preliminary Program
| DAY 1: Wednesday, June 13, 2007 |
|
08:00 |
Registration and Networking |
|
08:45 |
Welcoming Address
Dr. Michel J. Desrochers,
Director General
NRC Biotechnology Research Institute, Canada |
|
09:00 |
A Word from the Honorary President
Challenges of Commercialization of Industrial Biotechnology Innovations in Canada
Dr. Bernard M. Prigent, Medical Director ,
Vice President, Medical, Pfizer Canada Inc., Canada |
|
09:15 |
KEYNOTE SPEAKER
Trends in the Study of Protein Therapeutics
Dr. Janice M. Reichert, Senior Research Fellow,
Tufts University, Tufts Center for the Study of Drug Development, USA |
|
09:45 |
Break-Networking |
|
10:15 |
Session 1: Antibody-based Therapeutics
Chair: Dr. Daniel Chelsky, EVP & Chief Scientific Officer,
Caprion Proteomics, Canada |
|
|
Leading industrial researchers will offer insiders' view into the development of therapeutic antibodies. |
|
10:30 |
Application of Protein Engineering to Facilitate More Efficient Development of Antibodies from Discovery through Clinical Testing
Dr. Jeffry D. Watkins, Chief Scientific Officer,
Applied Molecular Evolution, Inc., USA |
|
11:00 |
Therapeutic Human Antibodies from Transgenic Mice: Unmodified, Optimized, and Drug-conjugated
Dr. Nils Lonberg, Senior Vice President, Scientific Director,
Medarex, USA |
|
11:30 |
Biopharmaceutical Drug Discovery by Protein Evolution
Dr. Lutz Jermutus, Director of Discovery - Oncology,
Cambridge Antibody Technology, United Kingdom |
|
12:00 |
Closing remarks - Session 1
Dr. Daniel Chelsky, EVP & Chief Scientific Officer,
Caprion Proteomics, Canada |
|
12:05 |
Networking Lunch |
|
13:30 |
Session 2: Protein Therapeutics
Chair: Dr. Maureen O'Connor, Group Leader, Receptors, Signaling & Proteomics,
NRC Biotechnology Research Institute, Canada |
|
|
Topics to be discovered include single-domain antibodies, non-antibody protein domains, novel design concepts and de-immunization of therapeutic proteins. |
|
13:45 |
Non-Antibody Proteins for Pharmaceutical Applications
Dr. Rainer Rudolph, Head of Protein Technology Group,
Martin-Luther University, Germany |
|
14:15 |
The Role of Protein Optimization in Improving the Pharmaceutical Properties of Biotherapeutic Candidates
Dr. John M. Beals, Senior Research Advisor,
Eli Lilly and Company, USA |
|
14:45 |
De-Immunization of Protein Therapeutics
Dr. Anne S. De Groot, Founder, CEO & CSO,
EpiVax, USA |
|
15:15 |
Discovery and Development of Single-Domain Antibodies
Dr. Roger MacKenzie, Project Leader, Antibody Engineering Project,
Immunochemistry Section, NRC Institute for Biological Sciences, Canada |
|
15:45 |
Coffee Break |
|
16:15 |
Multicomponent Traps – A Clinically Successful Approach to Engineering High Affinity Cytokine Blockers
Dr. Neil Stahl, Senior Vice President, Research & Development Sciences,
Regeneron Pharmaceuticals Inc., USA |
|
16:45 |
Design of combinatorial protein libraries with a built-in search engine to identify anticancer protein therapeutics
Jean Gariépy, Ph.D.
, Senior Scientist, Division of Cancer Genomics and Proteomics, Ontario Cancer Institute (OCI), Canada |
|
17:15 |
Closing remarks - Session 2
Dr. Maureen O'Connor, Group Leader, Receptors, Signaling & Proteomics,
NRC Biotechnology Research Institute, Canada |
|
17:20 |
Social Event - Networking |
DAY 2: Thursday, June 14, 2007 |
|
08:00 |
Registration and Networking |
|
08:45 |
Session 3: Protein and Peptide Mimetics
Chair: Dr. Philippe Walker, VP & Head, Discovery Montreal, Research Area CNS & Pain Control,
Astra Zeneca, Canada |
|
|
Presentations will outline strategies for further reducing the size of therapeutic proteins, including designer protein domains, multivalent polypeptides, hormone-like peptides, as well as mimetics of protein-binding sites. |
|
09:00 |
Designed Ankyrin Repeat Protein (DARPins)
Dr. Andreas Plückthun, Professor of Biochemistry,
Biochemisches Institut, Universität de Zürich, Switzerland |
|
09:30 |
Design and development of retractable bivalent polypeptides for therapeutic applications
Dr. Feng Ni
Group Leader, Biomolecular NMR and Protein Research,
NRC Biotechnology Research Institute, Canada |
|
10:00 |
Synthetic Mimicry of discontinuous protein binding sites for the modulation of protein-ligand interactions
Dr. Jutta Eichler, Head of Research Group CPLI,
Helmholtz Centre for Infection Research, Germany |
|
10:30 |
Making drugs out of long peptides
Dr. Krishna Peri, Vice President Research, Theratechnologies Inc, Canada |
|
11:00 |
Break - Networking |
|
11:30 |
Title to be confirmed
Dr. H. Uri Saragovi,
McGill University, Canada |
|
12:00 |
Closing Remarks - Session 3
Dr. Philippe Walker, Vice President, Discovery,
AstraZeneca R&D Montreal, Canada |
|
12:05 |
Networking Lunch |
|
13:00 |
Session 4: BioTransfer
Chair : Dr. Michel J. Desrochers, Director General
NRC Biotechnology Research Institute, Canada
Co-organizers:
Office of Technology Transfer - McGill University
NRC Industrial Research Assistance Program (NRC-IRAP) |
|
13:05 |
Introduction Remarks
Dr. Arthur T. Porter, Director General and CEO,
McGill University Health Centre (MUHC), Canada |
|
13:20 |
The new realities of financing drug discovery: Implications for Pharma and Biotech M&A and licensing Relationship.
Edward C. Saltzman,President,
Defined Health, USA |
|
13:55 |
Short Break |
|
|
Session 4A: Room A-34A
Chair: Mr. Yves Quenneville ,
Business development officer
NRC Biotechnology Research Institute, Canada
|
Session 4B: Room A-34B
Chair: Mr. Pierre Bourassa,
Industrial technology advisor
NRC Industrial Research Assistance Program, Canada
|
|
14:00 |
Novel Anti-Mitotic Peptides for the treatment of Cancer
Dr. Louise O'Donoughue, McGill University (04086) |
Computer-Aided Diagnosis Software for Neurological Diseases
Dr. Francoys Labonté, McGill University (04062) |
|
14:10 |
Peptides and proteins wound healing agents
Dr. John DiMaio, McGill University (04025) |
Carrier proteins for peptide production
Dr. Feng Ni, NRC-BRI (11391) |
|
14:20 |
Hybrid compounds for the treatment of refractory tumors
Dr. Michael Stern, McGill University (01057) |
High-Throughput Proteomics Pipeline
Dr. Francoys Labonté, McGill University (06013) |
|
14:30 |
Optimized soluble receptor as diagnostic and therapeutic tool
Dr. Maureen O'Connor-McCourt, NRC-BRI (11817) |
Assays for protein-protein interaction in the cytoplasm and/or on plasma membrane
Dr. Malcolm Whiteway, NRC-BRI (11681) |
|
14:40 |
Clusterin antibodies for cancer diagnostic and therapy
Dr. Maureen O'Connor-McCourt, NRC-BRI (11705) |
A cumate switch for protein production
Dr. Bernard Massie, NRC-BRI (11648) |
|
14:50 |
GIFT15, a biological immunosuppressant for systemic and ex-vivo treatment
Dr. Jacques Galipeau, McGill University (06087) |
Methylobacterium expression system
Dr. Carlos Miguez, NRC-BRI (11725) |
|
15:00 |
Cell Permeable Peptide for Treatment of Allergic Airway Diseases
Dr. Elizabeth Fixman, McGill University (05003) |
Expression systems for production of recombinant proteins in mammalian cells
Dr. Yves Durocher, NRC-BRI (11565) |
|
15:10 |
Peptide inhibitors of thrombin as potent anticoagulants
Dr. Feng Ni, NRC-BRI (11388) |
Baculovirus mediated transgene for protein expression
Dr. Alaka Mullick, NRC-BRI (11770) |
|
15:20 |
Biomolecular tweezers for drug discovery
Dr. Dmitri Tolkatchev, NRC-BRI (11615) |
Large scale transient transfection in mammalian cells
Dr. Yves Durocher, NRC-BRI (11266) |
|
15:30 |
Novel Vaccine Adjuvant
Dr. John DiMaio, McGill University (06048) |
Low cost high throughput antibody production
Dr. Astrid Reimann
, McGill University (06099) |
|
15:40 |
Nucleic acid hairpins as inhibitors of HIV RNAse H
Dr. Masad J. Damha
, McGill University (03050) |
Peptides to facilitate drug delivery
Dr. Orest Blaschuk
, McGill University (05012) |
|
15:50 |
Detection of intact recombinant viruses
Dr. Julia Transfiguracion, NRC-BRI (11622) |
FITTED 1.5: A Molecule Docking Software Program
Dr. Nicolas Moitessier, McGill University (06119) |
|
16:00 |
Closing Remarks - Session 4A
Mr. Yves Quenneville,
Business development officer
NRC Biotechnology Research Institute, Canada |
Closing Remarks - Session 4B
Chair: Mr. Pierre Bourassa,
Industrial technology advisor
NRC Industrial Research Assistance Program, Canada
|
|
 |
|
|
|
